CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CAR-T Cell Therapy: From the Shop to Cancer Therapy.
CAR-T Cell Therapy: From the Shop to Cancer Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
癌症是全球性的健康问题,免疫治疗领域的新技术不断涌现。嵌合抗原受体(CAR)技术是一种新型生物治疗方法;CAR-T 细胞基因工程已积极推动癌症免疫治疗变革。本文综述CAR-T 治疗癌症的最新进展,介绍不同代次及变体CAR-T 细胞的结构,包括TRUCK(重定向T细胞进行通用细胞因子杀伤)。我们阐释体外和体内制备CAR-T 细胞的方法,并描述该免疫疗法的局限和发展机会,以及CAR技术治疗血液系统肿瘤和实体瘤时面临的挑战、限制及工程改造策略。我们还总结采用CAR技术改造的其他免疫细胞,如自然杀伤(NK)细胞、巨噬细胞(M)和树突状细胞(DC)。我们认为,CAR-T 细胞不仅有望治疗癌症,也可能用于其他慢性疾病。
Cancer is a worldwide health problem. Nevertheless, new technologies in the immunotherapy field have emerged. Chimeric antigen receptor (CAR) technology is a novel biological form to treat cancer; CAR-T cell genetic engineering has positively revolutionized cancer immunotherapy. In this paper, we review the latest developments in CAR-T in cancer treatment.
We present the structure of the different generations and variants of CAR-T cells including TRUCK (T cells redirected for universal cytokine killing.
We explain the approaches of the CAR-T cells manufactured ex vivo and in vivo.
Moreover, we describe the limitations and areas of opportunity for this immunotherapy and the current challenges of treating hematological and solid cancer using CAR-T technology as well as its constraints and engineering approaches.
We summarize other immune cells that have been using CAR technology, such as natural killer (NK), macrophages (M), and dendritic cells (DC).
We conclude that CAR-T cells have the potential to treat not only cancer but other chronic diseases.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。